注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Revolution Medicines Inc是一家临床阶段精确肿瘤公司。该公司致力于开发靶向疗法,以抑制臭名昭著的生长和生存途径中难以捉摸的前沿靶点,特别强调肾素-血管紧张素系统(RAS)和雷帕霉素(mTOR)的哺乳动物靶点信号通路。该公司的研发(R&D)管道包括设计用于抑制多种RAS蛋白致癌变体的RAS(ON)抑制剂,以及用于联合治疗策略的RAS伴随抑制剂。其正在研发的RAS(ON)抑制剂包括RMC-6236、RMC-6291、RMC-9805和RMC-8839,以及一系列针对其他RAS变体的研究化合物。临床开发中的RAS伴随抑制剂包括RMC-4630(SHP2)和RMC-5552(mTORC1/4EBP1)。该公司的三复合物技术能够通过诱导新的药物囊袋来发现缺乏内在药物结合位点的靶点的小分子抑制剂。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Mark A. Goldsmith | 59 | 2014 | CEO, President & Chairman |
Kevan M. Shokat | - | 2016 | Academic Co-Founder & Member of Scientific Advisory Board |
Martin D. Burke | - | - | Co-Founder & Chairman of Scientific Advisory Board |
Michael A. Fischbach | 41 | 2016 | Academic Co-Founder & Member of Scientific Advisory Board |
Elizabeth McKee Anderson | 66 | 2015 | Independent Director |
Alexis A. Borisy | 51 | 2014 | Lead Independent Director |
Eric M. Gordon | - | 2016 | Senior Advisor & Member of Scientific Advisory Board |
John Kuriyan | - | 2016 | Senior Advisor & Member of Scientific Advisory Board |
Trever Bivona | - | 2016 | Senior Advisor & Member of Scientific Advisory Board |
Julian Adams | 68 | 2016 | Senior Advisor & Member of Scientific Advisory Board |
Barbara L. Weber | 66 | 2018 | Independent Director |
Flavia Borellini | 64 | 2021 | Independent Director |
Thilo Schroeder | 41 | 2018 | Independent Director |
Sue Gail Eckhardt | 65 | 2021 | Senior Advisor & Scientific Advisory Board Member |
Sushil Patel | 52 | 2022 | Independent Director |
Lorence H. Kim | 49 | 2022 | Independent Director |
Sandra J. Horning | 74 | 2023 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核